Central and regional hemodynamic effects of oral enoximone in congestive heart failure

A double-blind, placebo-controlled study

Carl V. Leier, John J. Lima, Steffen E Meiler, Donald V. Unverfeth

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Twelve patients with congestive heart failure underwent a double-blind, placebo-controlled study for the purpose of examining the central and regional hemodynamic effects of first-dose (1 and 2 mg/kg) oral enoximone, a new phosphodiesterase III inhibitor. Enoximone augmented cardiac output, generally through a positive chronotropic response. Indices of left ventricular contractility, specifically stroke volume, ΔP Δt, fractional shortening rate, and the duration of the preejection period, were only modestly enhanced by enoximone. At 2 mg/kg, systemic vascular resistance fell below baseline values without affecting systemic blood pressure; these parameters were not altered by the 1 mg/kg dose. Both pulmonary artery pressure and pulmonary vascular resistance dropped below baseline and below placebo control for the 2 mg/kg dose. Enoximone at 2 mg/kg lowered right and left heart filling pressures below baseline. Examination of regional hemodynamic responses to both doses demonstrated a reduction in limb vascular resistance and an increase in limb blood flow proportional to the concomitant increase in cardiac output. Renal and hepatic-splanchnic blood flow and vascular resistances were not altered by enoximone. First-dose oral enoximone (1 and 2 mg/kg) alters hemodynamics in heart failure by predominant vasodilatation, particularly of limb-musculoskeletal and pulmonary vascular beds, some positive chronotropism, and modest positive inotropism.

Original languageEnglish (US)
Pages (from-to)1051-1059
Number of pages9
JournalAmerican Heart Journal
Volume115
Issue number5
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Enoximone
Heart Failure
Hemodynamics
Placebos
Vascular Resistance
Extremities
Cardiac Output
Type 3 Cyclic Nucleotide Phosphodiesterases
Pressure
Phosphodiesterase Inhibitors
Viscera
Muscle Contraction
Vasodilation
Stroke Volume
Pulmonary Artery
Blood Vessels
Blood Pressure
Kidney
Lung
Liver

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Central and regional hemodynamic effects of oral enoximone in congestive heart failure : A double-blind, placebo-controlled study. / Leier, Carl V.; Lima, John J.; Meiler, Steffen E; Unverfeth, Donald V.

In: American Heart Journal, Vol. 115, No. 5, 01.01.1988, p. 1051-1059.

Research output: Contribution to journalArticle

@article{9bde93e17fd34167bd215a070bf3d479,
title = "Central and regional hemodynamic effects of oral enoximone in congestive heart failure: A double-blind, placebo-controlled study",
abstract = "Twelve patients with congestive heart failure underwent a double-blind, placebo-controlled study for the purpose of examining the central and regional hemodynamic effects of first-dose (1 and 2 mg/kg) oral enoximone, a new phosphodiesterase III inhibitor. Enoximone augmented cardiac output, generally through a positive chronotropic response. Indices of left ventricular contractility, specifically stroke volume, ΔP Δt, fractional shortening rate, and the duration of the preejection period, were only modestly enhanced by enoximone. At 2 mg/kg, systemic vascular resistance fell below baseline values without affecting systemic blood pressure; these parameters were not altered by the 1 mg/kg dose. Both pulmonary artery pressure and pulmonary vascular resistance dropped below baseline and below placebo control for the 2 mg/kg dose. Enoximone at 2 mg/kg lowered right and left heart filling pressures below baseline. Examination of regional hemodynamic responses to both doses demonstrated a reduction in limb vascular resistance and an increase in limb blood flow proportional to the concomitant increase in cardiac output. Renal and hepatic-splanchnic blood flow and vascular resistances were not altered by enoximone. First-dose oral enoximone (1 and 2 mg/kg) alters hemodynamics in heart failure by predominant vasodilatation, particularly of limb-musculoskeletal and pulmonary vascular beds, some positive chronotropism, and modest positive inotropism.",
author = "Leier, {Carl V.} and Lima, {John J.} and Meiler, {Steffen E} and Unverfeth, {Donald V.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1016/0002-8703(88)90076-2",
language = "English (US)",
volume = "115",
pages = "1051--1059",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Central and regional hemodynamic effects of oral enoximone in congestive heart failure

T2 - A double-blind, placebo-controlled study

AU - Leier, Carl V.

AU - Lima, John J.

AU - Meiler, Steffen E

AU - Unverfeth, Donald V.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Twelve patients with congestive heart failure underwent a double-blind, placebo-controlled study for the purpose of examining the central and regional hemodynamic effects of first-dose (1 and 2 mg/kg) oral enoximone, a new phosphodiesterase III inhibitor. Enoximone augmented cardiac output, generally through a positive chronotropic response. Indices of left ventricular contractility, specifically stroke volume, ΔP Δt, fractional shortening rate, and the duration of the preejection period, were only modestly enhanced by enoximone. At 2 mg/kg, systemic vascular resistance fell below baseline values without affecting systemic blood pressure; these parameters were not altered by the 1 mg/kg dose. Both pulmonary artery pressure and pulmonary vascular resistance dropped below baseline and below placebo control for the 2 mg/kg dose. Enoximone at 2 mg/kg lowered right and left heart filling pressures below baseline. Examination of regional hemodynamic responses to both doses demonstrated a reduction in limb vascular resistance and an increase in limb blood flow proportional to the concomitant increase in cardiac output. Renal and hepatic-splanchnic blood flow and vascular resistances were not altered by enoximone. First-dose oral enoximone (1 and 2 mg/kg) alters hemodynamics in heart failure by predominant vasodilatation, particularly of limb-musculoskeletal and pulmonary vascular beds, some positive chronotropism, and modest positive inotropism.

AB - Twelve patients with congestive heart failure underwent a double-blind, placebo-controlled study for the purpose of examining the central and regional hemodynamic effects of first-dose (1 and 2 mg/kg) oral enoximone, a new phosphodiesterase III inhibitor. Enoximone augmented cardiac output, generally through a positive chronotropic response. Indices of left ventricular contractility, specifically stroke volume, ΔP Δt, fractional shortening rate, and the duration of the preejection period, were only modestly enhanced by enoximone. At 2 mg/kg, systemic vascular resistance fell below baseline values without affecting systemic blood pressure; these parameters were not altered by the 1 mg/kg dose. Both pulmonary artery pressure and pulmonary vascular resistance dropped below baseline and below placebo control for the 2 mg/kg dose. Enoximone at 2 mg/kg lowered right and left heart filling pressures below baseline. Examination of regional hemodynamic responses to both doses demonstrated a reduction in limb vascular resistance and an increase in limb blood flow proportional to the concomitant increase in cardiac output. Renal and hepatic-splanchnic blood flow and vascular resistances were not altered by enoximone. First-dose oral enoximone (1 and 2 mg/kg) alters hemodynamics in heart failure by predominant vasodilatation, particularly of limb-musculoskeletal and pulmonary vascular beds, some positive chronotropism, and modest positive inotropism.

UR - http://www.scopus.com/inward/record.url?scp=0023952418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023952418&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(88)90076-2

DO - 10.1016/0002-8703(88)90076-2

M3 - Article

VL - 115

SP - 1051

EP - 1059

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -